Selpercatinib is the first drug from Loxo's pipeline that Lilly has brought to market.Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG.Although the company will continue to pursue "higher-risk, high reward" drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific...
